



Evodiamine as a novel antagonist of aryl hydrocarbon receptor

Hui Yu^{a,b,1}, Yongjiu Tu^{a,1}, Chun Zhang^a, Xia Fan^a, Xi Wang^a, Zhanli Wang^c, Huaping Liang^{a,*}

^a State Key Laboratory of Trauma, Burns, and Combined Injury, Department 1, Research Institute of Surgery, Daping Hospital, The Third Military Medical University, Chongqing 400042, China

^b Department of Laboratory Medicine, The Affiliated Tenth People's Hospital, Tongji University, Shanghai 200072, China

^c College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China

ARTICLE INFO

Article history:

Received 22 September 2010

Available online 1 October 2010

Keywords:

Aryl hydrocarbon receptor

Evodiamine

Docking

Homology modeling

Antagonist

ABSTRACT

Evodiamine, the major bioactive alkaloid isolated from Wu-Chu-Yu, has been shown to interact with a wide variety of proteins and modify their expression and activities. In this study, we investigated the interaction between evodiamine and the aryl hydrocarbon receptor (AhR). Molecular modeling results revealed that evodiamine directly interacted with the AhR. Cytosolic receptor binding assay also provided the evidence that evodiamine could interact with the AhR with the K_i value of 28.4 ± 4.9 nM. In addition, we observed that evodiamine suppressed the 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) induced nuclear translocation of the AhR and the expression of CYP1A1 dose-dependently. These results suggested that evodiamine was able to bind to the AhR as ligand and exhibit antagonistic effects.

© 2010 Elsevier Inc. All rights reserved.

1. Introduction

Evodiamine, the major bioactive alkaloid isolated and purified from Chinese herbal drug named Wu-Chu-Yu, has been reported to exhibit anti-inflammation, anti-tumor growth and anti-angiogenic activity [1]. Accumulating evidence suggests that evodiamine modulates various targets either through direct interaction or through modulation of gene expression, including vanilloid receptor, Bcl-2 and other gene products linked with cell survival, proliferation, invasion, and angiogenesis [2].

The AhR, a ligand-dependent transcription factor, is a member of the Per-Arnt-Sim family that has been detected in most cell and tissue types [3]. AhR includes a ligand binding domain (LBD) and interacts directly with specific ligands. The best-characterised AhR agonist is TCDD, which binds to the AhR with the highest affinity of all known compounds. Other agonists can be found endogenously and in the diet [4,5]. Following agonist binding, the AhR translocates to the nucleus, forms a heterodimer with aryl hydrocarbon receptor nuclear transporter protein (ARNT), and modulate the expression of a number of genes, including cytochrome P450 1A1, 1A2, 1B1, glutathione S transferase M (GSTM), aldehyde dehydrogenase and oncogenes [6–9]. Moreover, some natural compounds have been reported to interact with the AhR and induce or inhibit the AhR transformation [10–14].

In this study, we investigated the specific interaction of evodiamine with AhR using computational approaches, and the interaction mechanism was discussed. We also investigated the inhibitory effect of evodiamine on the specific binding between the AhR and TCDD using cytosolic AhR binding assay. Moreover, we evaluated the antagonistic effects of evodiamine on the transformation of the AhR and its downstream events. We showed for the first time that evodiamine interacted with the AhR and was a potent antagonist of the AhR.

tion mechanism was discussed. We also investigated the inhibitory effect of evodiamine on the specific binding between the AhR and TCDD using cytosolic AhR binding assay. Moreover, we evaluated the antagonistic effects of evodiamine on the transformation of the AhR and its downstream events. We showed for the first time that evodiamine interacted with the AhR and was a potent antagonist of the AhR.

2. Materials and methods

2.1. Materials

TCDD (purity 99%) and [³H]-TCDD (specific activity 33 Ci/mmol) were purchased from Anal-tech Science Limited (ShenZhen, China). Evodiamine (purity 99%) was purchased from Xi'an Guanyu Biotechnology Company Limited (Xi'an, China). All ligands were dissolved in DMSO. The DMSO concentration in the cell culture medium was below 0.1%. RPMI-1640 medium and fetal calf serum were purchased from Gibco BRL (Gaithersburg, Maryland, USA). DMSO was purchased from Sigma-Aldrich (St Louis, Missouri, USA). The following primary antibodies were used in this study: AhR, CYP1A1 (Santa Cruz Biotechnology, Santa Cruz, California, USA).

2.2. Homology modeling

We selected the PAS domain structure of hypoxia-inducible factor 2 α (Hif-2 α) (PDB code: 2A24) as the 3D coordinate template for the homology modeling of human AhR-LBD [15]. The primary amino acid sequence of the AhR-LBD (Genbank: NP_001612) was

* Corresponding author. Fax: +86 23 68757404.

E-mail address: huaping_liang@yahoo.com.cn (H. Liang).

¹ These authors contributed equally to this study.

aligned with that of the template using Clustal W [16] with default settings. The gap penalties used were a gap opening penalty of ten and a gap extension penalty of 0.05. Three-dimensional model of the human AhR-LBD was constructed based on the structure of template using program Modeller. The entire model was globally energy minimized in the presence of explicit solvent model TIP3P water using the CHARMM program. The obtained structure was evaluated with the Verify3D programs.

2.3. Molecular docking

The human AhR-LBD model was used as a template for docking experiments with the ligands. The eHiTS software package was used for flexible docking [17]. The ligand was docked to the AhR-LBD model using the accuracy mode of docking (accuracy set to six) and scored with eHiTS Score, which is included in the eHiTS software package.

2.4. Cytosolic receptor binding assay

Wistar rats were purchased from third military medical university (Chongqing, China). The animals were housed in cages under standard laboratory conditions (24 °C, 60% humidity, 12 h dark/light cycle) and were given 3 days to adapt to standard laboratory conditions. These animals were used for cytosol preparation following liver perfusion. Liver cytosol from Wistar rats was prepared as previously described [18]. The IC_{50} and K_i values for competitive receptor binding affinities were determined using frozen rat hepatic cytosol (2 mg protein/ml) and the hydroxyapatite (HAP) procedure essentially as described using 1 nM [3H]-TCDD as the radioligand [19]. Different concentrations of evodiamine or unlabeled TCDD were used to determine displacement curves. The IC_{50} values were defined as the concentrations required to displace 50% of the [3H]-TCDD and were determined from a probit plot of the percentage of [3H]-TCDD bound versus log concentrations of the ligand. K_i values were determined by the methods of Cheng and Prusoff [20].

2.5. Cell culture and chemical treatment

Human Lovo cells were derived from the American Type Culture Collection (ATCC, Rockville, MD). Cells were maintained in RPMI-1640 medium containing 10% heat-inactive fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified incubator at 37 °C in 5% CO_2 . 0.1 µM TCDD, different concentrations of evodiamine, and TCDD plus evodiamine were dissolved in DMSO (0.1%) and added to the culture dishes when the cells reached 70% confluence. Cells were harvested 24 h after chemical treatment.

2.6. Immunocytochemistry

After different chemical treatment, Lovo cells were then fixed in 4% paraformaldehyde for 30 min, blocked with 5% bovine serum albumin (BSA), stained with rabbit polyclonal anti-AhR (1:100 dilution) overnight at 4 °C. Subsequently, these cells were incubated with FITC-conjugated mouse anti-rabbit antibody (1:200) for 1 h. Cell nuclei was stained with 10 mg/ml DAPI and representative photographs were obtained under a laser confocal scanning microscope.

2.7. Real-time PCR

Total RNA from harvested human Lovo cells was extracted with TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Quantitative real-time PCR analysis was performed

by LightCycler (Roche) and SYBR RT-PCR kit (Takara, Dalian, China). The following primer sets were utilized: CYP1A1 FP 5'-TCC TTG TGA TCC CAG GCT C-3', CYP1A1 RP 5'-CCA GGT GCG GGT TCT TT-3', GAPDH FP 5'-GGG AAA CTG TGG CGT GAT-3', GAPDH RP 5'-GAG TGG GTG TCG CTG TTG A-3'. Data were normalized by the level of GAPDH expression in each sample.

2.8. Western blot assay

Lovo cells were harvested and washed twice in ice-cold PBS. The cells were lysed with lysis buffer, then centrifuged at 13,000g for 15 min at 4 °C. The protein concentration was determined by a BCA protein assay kit. Protein was loaded onto SDS-PAGE gel and electro-transferred to polyvinylidene fluoride membranes. After being blocked with 5% non-fat milk, the membranes were incubated with mouse monoclonal anti-CYP1A1 followed by horseradish peroxidase conjugated rabbit anti-mouse secondary antibody. Finally, the membranes were visualized with an enhanced chemiluminescence kit.

2.9. Statistical analysis

All the experiments were carried out in triplicate, and the results are expressed as means $\pm$ SD. Statistical significance was determined by performing ANOVA using Student's *t*-test.

3. Results and discussion

3.1. Homology modeling of the human AhR-LBD

To construct the homology model of the human AhR-LBD, sequence alignments of the human AhR-LBD and the template were carried out (Fig. S1). The sequence identity between two proteins is low (27%). However, there is a high structural conservation of the α and β folds [21]. Therefore, we selected the PAS domain structure of Hif-2 α for generating a 3D model of the human AhR-LBD based on its closest similarity in this region. The homology model of the human AhR-LBD was obtained using the primary amino acid sequence [283–390] of the human AhR (Fig. 1). The refined homology model was then geometrically corrected so that all of the residues were in sterically allowed regions of the Ramachandran plot (Fig. S2). Moreover, the Verify3D evaluation was also performed, the overall self-compatibility scores for the predicted structures were all above the expected values (Fig. S3). Our results indicated that the predicted model was reliable.




Fig. 1. Homology model of the human AhR-LBD with the protein backbone displayed as ribbon and colored by secondary structure (Discovery Studio Visualizer 2.5, Accelrys).

Download English Version:

<https://daneshyari.com/en/article/1930994>

Download Persian Version:

<https://daneshyari.com/article/1930994>

[Daneshyari.com](https://daneshyari.com)